Supporting the World's Biggest Challenges

Croda International Plc (Croda) today announced that it has signed two new partnership agreements that will help the pharmaceutical industry move towards a more sustainable supply chain for vaccine adjuvants. 

To this day, our focus has been to successfully develop, manufacture and market high-quality adjuvants for our pharmaceutical customers. This heritage makes our vaccine adjuvants unique in the industry. A heritage we are proud of. 

Our industry-leading, Alhydrogel®, Adju-Phos® and Quil-A® are widely recognised in the vaccine industry for their unmatched track record when it comes to a proven history of safe and effective use.

Formulating a drug for parenteral delivery comes with its fair set of challenges. Aside from a high level of sensitivity to external factors like light and heat exposure, these large and complex drugs are prone to degradation when exposed to various chemical species.